Issues
-
Cover Image
Cover Image
Inactivation of the tumor suppressor p53 frequently occurs in tumors and tumor-associated stromal cells. This study shows that p53 dysfunction in tumor-associated stroma of B16F1 melanoma favors tumor establishment and progression by promoting an inflammatory microenvironment. Using immunofluoresence, it was found that lymphoid-like fibroblastic reticular cells, which express ER-TR7 (green), GP38 (red), and a-SMA (blue), were markedly expanded in the tumor microenvironment lacking functional p53. The expansion of this specialized stromal network was associated with augmented myeloid derived suppressor cells and angiogenesis. For details, see the article by Guo and colleagues on page 1668. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Reviews
Meeting Reports
Priority Reports
Clinical Studies
Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein–Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients
Integrated Systems and Technologies
Microenvironment and Immunology
Therapeutic Efficacy of Bifunctional siRNA Combining TGF-β1 Silencing with RIG-I Activation in Pancreatic Cancer
Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
Molecular and Cellular Pathobiology
Transcription Factor YY1 Contributes to Tumor Growth by Stabilizing Hypoxia Factor HIF-1α in a p53-Independent Manner
Dormant Cancer Cells Contribute to Residual Disease in a Model of Reversible Pancreatic Cancer
xCT Inhibition Depletes CD44v-Expressing Tumor Cells That Are Resistant to EGFR-Targeted Therapy in Head and Neck Squamous Cell Carcinoma
Prevention and Epidemiology
Therapeutics, Targets, and Chemical Biology
Mixed Lineage Kinase MLK4 Is Activated in Colorectal Cancers Where It Synergistically Cooperates with Activated RAS Signaling in Driving Tumorigenesis
Tumor and Stem Cell Biology
Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway
FOXC2 Expression Links Epithelial–Mesenchymal Transition and Stem Cell Properties in Breast Cancer
Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity
Genetic Amplification of the NOTCH Modulator LNX2 Upregulates the WNT/β-Catenin Pathway in Colorectal Cancer
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.